Markets:

Overview

News

Currencies

International

Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.97 -0.10 (-0.59%)

Streaming Delayed Price Updated: 12:07 PM EDT, Sep 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

April 17, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform

April 13, 2023

From Bausch + Lomb

Via Business Wire

Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

April 12, 2023

From Bausch + Lomb Corporation

Via Business Wire

Analyst Expectations for Bausch & Lomb's Future ↗

March 23, 2023

Via Benzinga

The Latest Analyst Ratings for Bausch & Lomb ↗

February 24, 2023

Via Benzinga

7 Analysts Have This to Say About Bausch & Lomb ↗

December 21, 2022

Via Benzinga

What 7 Analyst Ratings Have To Say About Bausch & Lomb ↗

November 23, 2022

Via Benzinga

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

March 22, 2023

From Bausch + Lomb Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗

March 09, 2023

Via Benzinga

Expert Ratings for Bausch & Lomb ↗

November 03, 2022

Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter:

Via Benzinga

What 4 Analyst Ratings Have To Say About Bausch & Lomb ↗

October 11, 2022

Analysts have provided the following ratings for Bausch & Lomb (NYSE:BLCO) within the last quarter:

Via Benzinga

What 4 Analyst Ratings Have To Say About Bausch & Lomb ↗

September 12, 2022

Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter:

Via Benzinga

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

February 22, 2023

From Bausch + Lomb Corporation

Via Business Wire

Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday ↗

February 15, 2023

U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

February 15, 2023

From Bausch + Lomb Corporation

Via Business Wire

Expert Ratings for Bausch & Lomb ↗

September 12, 2022

Within the last quarter, Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings:

Via Benzinga

New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients

February 07, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)

February 01, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

January 23, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Acquires AcuFocus, Inc.

January 17, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

January 09, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

January 09, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

January 05, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

January 04, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month

January 03, 2023

From Bausch + Lomb Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗

December 21, 2022

Via Benzinga

Battered FTX's CEO Sam Bankman-Fried Arrested, Elon Musk's SpaceX Mammoth Valuation Of $140B, China Weighs Over $143B In Semiconductor Push: Top Stories Tuesday, Dec. 13 ↗

December 13, 2022

Benzinga Sam Bankman-Fried Arrested In The Bahamas

Via Benzinga

Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits ↗

December 13, 2022

More than 50 funds that own Bausch Health Companies Inc (NYSE: BHC) investors are reportedly seeking to block the eye-care business spin-off, Bausch + Lomb Corp (NYSE: BLCO).

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022 ↗

September 12, 2022

Upgrades

Via Benzinga

From Corporate Raider To Activist Investor: Here Are Three High-Yielding Stocks Carl Icahn Favors ↗

August 28, 2022

Formerly known as a "corporate raider," Carl Icahn is the founder and controlling shareholder of Icahn Enterprises, which is a large holding company with well diversified positions.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.